Technical analysis of Barinthus Biotherapeutics plc (BRNS): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease.
Price Performance
| 1 month | +22.86% |
| 3 months | +11.75% |
| Year-to-date | +5.70% |
| 1 year | -33.33% |
| 3 years | -57.71% |
52-Week Range
| 52-week High | $1.83 |
| 52-week Low | $0.51 |
| Avg Volume (90d) | 73K |
Technical Indicators
| SMA 50 | $0.64 |
| SMA 200 | $0.66 |
| Beta | -0.60 |
| 30-day Volatility (annualised) | 66.7% |
| Price vs SMA 50 | +16.2% |
| Price vs SMA 200 | +12.3% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $1.32 | |
| 2025-11 | $0.79 | -40.2% |
| 2025-12 | $0.70 | -11.4% |
| 2026-01 | $0.73 | +4.3% |
| 2026-02 | $0.58 | -20.0% |
| 2026-03 | $0.57 | -2.6% |
| 2026-04 | $0.65 | +14.2% |
| 2026-05 | $0.68 | +4.7% |
| 2026-06 | $0.66 | -3.0% |
| 2026-07 | $0.56 | -15.5% |
| 2026-08 | $0.70 | +25.0% |
| 2026-09 | $0.74 | +6.2% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-16 | $-0.07 | $51M |
| 2026-09-16 | $0.14 | $705M |
| 2026-09-16 | | |
| 2026-09-16 | | $5M |
| 2026-09-16 | | |
| 2026-09-16 | $0.24 | $4.55B |
Price
| Price | $0.74 |
| Market Cap | $30M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.53 |
| EV / EBITDA | 0.48 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.18 |
| Current Ratio | 5.54 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -4.62 |